August 1st, 2018

The American Society for Pharmacology & Experimental Therapeutics (ASPET)

Contact: Tyler Lamb
Phone: (301) 634-7062
E-mail: tlamb@aspet.org

Rockville, MD - Following the White House’s announcement that President Trump intends to nominate Kelvin Droegemeier, PhD, to be the next director of the Office of Science and Technology Policy, the American Society for Pharmacology & Experimental Therapeutics (ASPET) issued the following statement:

“AsPET applauds President Trump’s decision to nominate Kelvin Droegemeier, PhD, to be director of the White House office of Science and Technology Policy. Dr. Droegemeier is a well-qualified and highly regarded scientist with a strong background in science policy. He is an excellent choice to lead the administration’s scientific advisory body, and ASPET urges the Senate to confirm him expeditiously.

A renewed commitment to scientific research on the part of the administration is crucial to improving the lives of all Americans. ASPET is hopeful that Dr. Droegemeier’s nomination signals an openness to crafting a science policy agenda that will maintain our country’s research preeminence.”

###

*The American Society for Pharmacology and Experimental Therapeutics (ASPET) is a 5,000 member scientific society whose members conduct basic and clinical pharmacological research and work for academia, government, large pharmaceutical companies, small biotech companies, and non-profit organizations.*